Connect MDS/AML: Design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  Steensma, David P ^a   Abedi, Medrdad ^b   Bejar, Rafael ^c   Cogle, Christopher R ^d   Foucar, Kathryn ^e   Garcia Manero, Guillermo ^f   George, Tracy I ^e   Grinblatt, David ^g   Komrokji, Rami ^h   Ma, Xiaomei ⁱ   Maciejewski, Jaroslaw ^j   Pollyea, Daniel A ^k   Savona, Michael R ^l   Scott, Bart ^m   Sekeres, Mikkael A ^j   Thompson, Michael A ⁿ   Swern, Arlene S ^o   Nifenecker, Melissa ^o   Sugrue, Mary M ^o   Erba, Harry ^p  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ YALE UNIVERSITY   (United States)

^j LERNER RESEARCH INSTITUTE   (United States)

^k UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^l VANDERBILT INGRAM CANCER CENTER   (United States)

^m USA   (United States)

ⁿ Aurora Health Care   (United States)

^o CELGENE CORPORATION   (United States)

^p Heerskink School of Medicine   (United States)

more..

Author keywords

Acute myeloid leukemia; Biomarkers; Clinical outcomes; Clonal hematopoiesis of indeterminate potential (CHIP); Idiopathic cytopenia of undetermined significance; Myelodysplastic syndromes; Patient reported outcomes; Registry; Treatment patterns

Indexed keywords

AZACITIDINE; DECITABINE; LENALIDOMIDE; TUMOR MARKER;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER REGISTRY; CANCER THERAPY; COHORT ANALYSIS; CONTROLLED STUDY; ELECTRONIC MEDICAL RECORD SYSTEM; HEALTH ECONOMICS; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INTERMEDIATE RISK PATIENT; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; INTERVENTION STUDY; KARYOTYPE; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT INFORMATION; PROSPECTIVE STUDY; QUALITY OF LIFE; RISK ASSESSMENT; UNITED STATES; FEMALE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REGISTER; SAMPLE SIZE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROSPECTIVE STUDIES; QUALITY OF LIFE; REGISTRIES; SAMPLE SIZE; UNITED STATES;

EID: 84982234151     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-2710-6     Document Type: Article

References (33)

1. Cazzola M, Malcovati L. Myelodysplastic syndromes--coping with ineffective hematopoiesis. N Engl J Med. 2005;352(6):536-8.
2. Steensma DP. Myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc. 2015;90(7):969-83.
3. Vardiman JW. Hematopathological concepts and controversies in the diagnosis and classification of myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2006;199-204.
4. Liesveld JL, Lichtman MA. Acute myelogenous leukemia. In: Lichtman MA, editor. Williams hematology. 7th ed. New York: McGraw-Hill; 2005. p. 1183-236.
5. Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: a review. Br J Haematol. 2011;152(5):524-42.
6. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51.
7. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-302.
8. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res. 2007;31(6):727-36.
9. Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9-16.
10. Bejar R. Myelodysplastic syndromes diagnosis: what is the role of molecular testing? Curr Hematol Malig Rep. 2015;10(3):282-91.
11. Valent P, Bain BJ, Bennett JM, Wimazal F, Sperr WR, Mufti G, et al. Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. Leuk Res. 2012;36(1):1-5.
12. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2012. Bethesda: National Cancer Institute. http://seer.cancer.gov/csr/1975_2012/ , based on November 2014 SEER data submission, posted to the SEER web site, April 2015.
13. Cogle CR, Craig BM, Rollison DE, List AF. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011;117(26):7121-5.
14. Bejar R, Steensma DP. Recent developments in myelodysplastic syndromes. Blood. 2014;124(18):2793-803.
15. Cogle CR. Incidence and burden of the myelodysplastic syndromes. Curr Hematol Malig Rep. 2015;10(3):272-81.
16. Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010;28(17):2847-52.
17. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology™ myelodysplastic syndromes. 2015. Version 1.2016.
18. Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008;22(3):538-43.
19. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.
20. Nazha A, Narkhede MS, Radivoyevitch T, Kalaycio M, Patel BJ, Gerds AT, et al. The Revised International Prognostic Scoring System "Molecular" (IPSS-Rm), a Validated and Dynamic Model in Treated Patients with Myelodysplastic Syndromes (MDS). Blood. 2015;126(23). [ASH abstract 607].
21. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: acute myeloid leukemia. 2015. Version 1.
22. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Network. Blood. 2010;115(3):453-74.
23. Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122(17):2943-64.
24. Klepin HD, Rao AV, Pardee TS. Acute myeloid leukemia and myelodysplastic syndromes in older adults. J Clin Oncol. 2014;32(24):2541-52.
25. Steensma DP, Komrokji RS, Stone RM, List AF, Garcia-Manero G, Huber JM, et al. Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes. Cancer. 2014;120(11):1670-6.
26. Ossenkoppele G, Lowenberg B. How I treat the older patient with acute myeloid leukemia. Blood. 2015;125(5):767-74.
27. Cherubini A, Pierri F, Gasperini B, Zengarini E, Cerenzia A, Bonifacio E, et al. Are ongoing trials on hematologic malignancies still excluding older subjects? Haematologica. 2013;98(7):997-1000.
28. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-88.
29. Thein MS, Ershler WB, Jemal A, Yates JW, Baer MR. Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades. Cancer. 2013;119(15):2720-7.
30. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34(3 Suppl 2):13-9.
31. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337-43.
32. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. JAMA. 1997;277(11):927-34.
33. Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, et al. Good publication practice for communicating company-sponsored medical research: GPP3. Ann Intern Med. 2015;163(6):461-4.